Released: December 16, 2021
Department of Defense
Congressionally Directed Medical Research Programs (CDMRP)
Ovarian Cancer Research Program
Anticipated Funding Opportunities for Fiscal Year 2022 (FY22)
The FY22 Defense Appropriations Bill has not been signed into law. Although FY22 funds have not been appropriated for the Ovarian Cancer Research Program (OCRP), the OCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY22 funding opportunities. This pre-announcement should not be construed as an obligation by the Government.
The FY22 Defense Appropriations Act is anticipated to provide funding for the OCRP to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of Service Members, Veterans, their family members, and all women impacted by this disease. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation appropriation. The managing agent for the anticipated program announcements/funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).
The OCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY22 funding opportunities. This pre-announcement should not be construed as an obligation by the government. The FY22 OCRP funding opportunity announcements for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the announcements are released.
Applications submitted to the FY22 OCRP must address one or more of the following areas of emphasis:
- Understand the basic biology and etiology of ovarian cancer initiation, progression, metastasis, recurrence, genetics and other critical events
- Develop novel therapeutic strategies for treatment and prevention
- Identify and develop new strategies for screening, early-stage detection, prevention, accurate diagnosis and prognosis
- Identify and implement strategies to improve the survivorship and quality of life
- Address health disparities
- Address precision medicine
Alternatively, with adequate justification, applications may identify and address another area of importance related to the ovarian cancer. Justification must be provided in the application.
|Award Mechanism||Eligibility||Key Mechanism Elements||Funding|
|Investigator-Initiated Research Award||Must be at or above the level of Assistant Professor (or equivalent).
Partnering Principal Investigator (PI) Option:
|Ovarian Cancer Academy Award – Early-Career Investigator||Investigators must be within 5 years of their last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.), or equivalent as of the full application submission deadline. A letter attesting to eligibility is required.||
|Pilot Award||Investigators must be at or above the postdoctoral level (or equivalent).||
|Teal Expansion Award||Investigators of the following awards:
|Proteogenomics Research Award||Investigators must be at or above the level of postdoctoral fellow or clinical fellow (or equivalent).||
|Ovarian Cancer Academy – Clinical Trial Award||NEW! Investigators must be an independent ovarian cancer investigator with strong record of mentoring and leadership experience.||
|Clinical Trial Award||NEW! Independent investigators at all academic levels||
A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final funding opportunity announcements that will be available for downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
Submission deadlines are not available until the funding opportunity announcements are released. For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the OCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).
Point of Contact:
CDMRP Public Affairs
Last updated Tuesday, January 4, 2022